Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein apheresis in the era of new lipid-lowering therapies.

European heart journal·2026
Same author

Treatment of Clinically Diagnosed Alzheimer's Disease by External Counterpulsation A Randomized Clinical Trial.

American journal of Alzheimer's disease and other dementias·2026
Same author

Lp(a): A potentially modifiable cardiovascular risk factor.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.

European journal of preventive cardiology·2026
Same author

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.

Atherosclerosis·2026
Same author

Assessing pharmacists' knowledge and practices involving dietary supplement omega-3 fatty acids.

Journal of clinical lipidology·2025

Related Experiment Video

Updated: Jun 18, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Does simvastatin cause more myotoxicity compared with other statins?

James M Backes1, Patricia A Howard, Janelle F Ruisinger

  • 1Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS 66160, USA. jbackes@kumc.edu

The Annals of Pharmacotherapy
|November 19, 2009
PubMed
Summary

Simvastatin, a common statin, may carry a higher risk of muscle toxicity at its 80 mg dose compared to other statins. While overall statin-induced myotoxicity is rare, individualized therapy is recommended.

Related Experiment Videos

Last Updated: Jun 18, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

  • Pharmacology
  • Clinical Therapeutics
  • Drug Safety

Background:

  • Statins are widely used to manage hyperlipidemia.
  • Myotoxicity is a known, albeit rare, adverse effect associated with statin therapy.
  • Concerns exist regarding differential myotoxicity risks among various statin agents.

Purpose of the Study:

  • To conduct a literature review on statins and myotoxicity.
  • To evaluate existing data on simvastatin's myotoxicity risk compared to other statins.

Main Methods:

  • Searched MEDLINE and International Pharmaceutical Abstracts (1966-2009).
  • Included English-language articles on statin myotoxicity and drug interactions in humans.
  • Key search terms included statin names, myotoxicity, myopathy, myalgia, and rhabdomyolysis.

Main Results:

  • Simvastatin, a moderate-potency statin, may have a higher risk of severe muscle toxicity, especially with cytochrome P450 inhibitors.
  • Low-to-moderate doses of simvastatin show infrequent myotoxicity, similar to other statins.
  • The 80 mg daily dose of simvastatin suggests a possible increase in myotoxicity rates compared to lower doses and other statins' maximum doses.

Conclusions:

  • Severe myotoxicity rates with all statins are generally low, particularly at low-to-moderate doses.
  • Recent trials indicate a higher incidence of myotoxicity with simvastatin 80 mg daily versus other statins' maximum doses.
  • Healthcare providers should personalize statin therapy, considering potential risks to minimize myotoxicity.